Jean E. Surfus

Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2.

Jacquelyn A. Hank, Randy Robinson, Jean E. Surfus et al. · PubMed · 1990 · 156 citations

Pharmacy, Immunology, Oncology +17

Phase I Clinical Trial of the Immunocytokine EMD 273063 in Melanoma Patients

David M. King, Mark R. Albertini, Heidi Schalch et al. · Journal of Clinical Oncology · 2004 · 146 citations · Full text

Medicine, Oncology, Pharmacology +17

Treatment of Neuroblastoma Patients with Antiganglioside GD2 Antibody plus Interleukin-2 Induces Antibody-Dependent Cellular Cytotoxicity Against Neuroblastoma Detected In Vitro

Jacquelyn A. Hank, Jean E. Surfus, Jacek Gan et al. · Journal of Immunotherapy · 1994 · 76 citations

Life Sciences, Immunology, Oncology +16

Anti-Renal-Cell Carcinoma Chimeric Antibody G250 Facilitates Antibody-Dependent Cellular Cytotoxicity with In Vitro and In Vivo Interleukin-2-Activated Effectors

Jean E. Surfus, Jacquelyn A. Hank, Egbert Oosterwijk et al. · Journal of Immunotherapy · 1996 · 74 citations · Full text

Medicine, Cancer Biology, Oncology +17

Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2).

Jacquelyn A. Hank, Jean E. Surfus, J. Gan et al. · PubMed · 1996 · 71 citations

Life Sciences, Immunology, Oncology +14